Related by context. All words. (Click for frequent words.) 66 goserelin 63 prucalopride 63 MoxDuo TM IR 63 RAPAFLO 62 teriflunomide 62 subcutaneously administered 62 CIMZIA TM 61 Traficet EN 61 rHuPH# 61 Capesaris 61 interferon beta 1b 61 PSMA ADC 61 cangrelor 61 BAL# [002] 61 HuMax CD4 61 CCX# 61 Pimavanserin 61 APTIVUS 60 analgesic efficacy 60 MAGE A3 ASCI 60 Neurodex 60 #mg dose [001] 60 ibandronate 60 decitabine 60 CIMZIA ™ 60 Androxal TM 60 tocilizumab 60 forodesine 60 icatibant 60 administered subcutaneously 60 talabostat 60 Sym# 60 Phase IIB 59 mg kg dose 59 ACZ# 59 mertansine 59 mg dose 59 Amrubicin 59 maximally tolerated dose 59 lapatinib Tykerb 59 PEGPH# 59 Natalizumab 59 divalproex sodium 59 CR# vcMMAE 59 EndoTAG TM -1 59 JAK inhibitor 59 ancrod 59 glatiramer acetate 59 USL# 59 phase IIa clinical 59 Cethromycin 59 TREDAPTIVE 59 Darusentan 59 Phase Ib study 59 Phase 2a trial 59 desvenlafaxine succinate 58 Fulvestrant 58 GAMMAGARD 58 ONTAK 58 pomalidomide 58 Bezielle 58 INCB# [001] 58 TKM ApoB 58 Dapagliflozin 58 double blinded placebo 58 visilizumab 58 vorinostat 58 Menerba 58 sitaxsentan 58 APRISO 58 TBC# 58 Panzem R NCD 58 idraparinux 58 phase IIb trial 58 PEG SN# 58 nitazoxanide 58 BENICAR HCT 58 alicaforsen enema 58 cannabinor 58 Pennsaid R 58 AEGR 58 febuxostat 58 elotuzumab 58 Onconase 58 DAPT 58 HuMax CD# 58 vidofludimus 58 tezampanel 58 oral rivaroxaban 58 Bicifadine 58 Targretin 58 Dalbavancin 58 NasalFent 58 Ophena 58 PRT# 58 GFT# 57 YONDELIS 57 BRIM2 57 teduglutide 57 Dabigatran etexilate 57 ENMD # 57 liposomal formulation 57 dose cohort 57 velafermin 57 oral ridaforolimus 57 salmeterol fluticasone 57 CoFactor 57 enzastaurin 57 ACTIVE W 57 alvespimycin 57 ziprasidone 57 VA# [002] 57 HuLuc# 57 lanthanum carbonate 57 AZILECT R 57 CANCIDAS 57 canakinumab 57 oral prodrug 57 MoxDuo IR 57 Phase 2b study 57 LibiGel ® 57 adalimumab 57 lisdexamfetamine dimesylate 57 ACTEMRA TM 57 PROMACTA 57 Phase 1b trial 57 mycophenolate mofetil 57 certolizumab 57 BYSTOLIC 57 octreotide acetate 57 Azedra 57 efficacy endpoint 57 alvimopan 57 phase Ib 57 pharmacokinetic PK profile 57 FOLPI 57 CaPre TM 57 Phase Ib II 57 Vidofludimus 57 zafirlukast 57 mITT population 57 pegylated liposomal doxorubicin 57 midstage clinical 57 cilengitide 57 DXL# 57 Alocrest 57 dosage regimens 57 antiplatelet agent 57 protease inhibitor PI 57 pharmacokinetic PK study 57 mecamylamine 57 EFAPROXYN 57 tapentadol ER 57 favorable pharmacokinetic profile 57 HuMax EGFr 57 tasimelteon 56 subcutaneous SC 56 Phase Ib clinical 56 Zemplar Capsules 56 GnRH antagonist 56 APTIVUS r 56 adipiplon 56 zonisamide SR 56 MoxDuo 56 LT NS# 56 tacrolimus ointment 56 DAVANAT 56 thymalfasin 56 ISIS # 56 Aflibercept 56 bendamustine 56 brivaracetam 56 Nuvion 56 ORENCIA ® 56 Onbrez Breezhaler 56 eltrombopag 56 randomized blinded 56 volociximab 56 ocrelizumab 56 dalteparin 56 TG# [003] 56 BRAF inhibitor 56 fluticasone furoate 56 HGS ETR2 56 Chemophase 56 antiarrhythmic drug 56 Tolvaptan 56 placebo controlled clinical 56 AGGRASTAT ® 56 AZILECT ® 56 phase IIIb 56 Hyphanox 56 custirsen 56 pertuzumab 56 PD LID 56 galantamine 56 orBec 56 iclaprim 56 mcg dose 56 indibulin 56 NEVO ™ 56 Tarceva TM 56 Q#IR 56 Civacir 56 TriRima 56 sipuleucel T 56 rilonacept 56 isavuconazole 56 rFIXFc 56 Omacetaxine mepesuccinate 56 GVAX 56 immunomodulator 56 EOquin TM 56 ascending dose 56 davunetide intranasal AL 56 RELOVAIR ™ 56 azacitidine 56 huN# DM1 56 reslizumab 56 senicapoc 56 CRx 56 teriparatide 56 Corlux 56 zileuton 56 phase IIb clinical 56 SinuNase 56 relapsing multiple sclerosis 56 CBLC# 56 HCV SPRINT 56 HGS# 55 antiandrogens 55 REMINYL ® 55 balsalazide tablet 55 CorVue ™ 55 Pemetrexed 55 tipranavir 55 Targretin capsules 55 Engerix B 55 Rebif ® 55 anidulafungin 55 subcutaneous formulation 55 efavirenz EFV 55 HGS ETR1 55 Aclidinium 55 Phase 1a clinical 55 QLT# 55 comparator arm 55 inhibitor RG# 55 subcutaneous ORENCIA 55 Panzem R 55 pegaptanib 55 orally dosed 55 ALGRX 55 Interferon alpha 55 Myocet 55 torezolid phosphate 55 ADVANCE PD 55 preclinically 55 INC# 55 pitavastatin 55 cobiprostone 55 FTY# 55 VELCADE melphalan 55 DermaVir Patch 55 delafloxacin 55 ZACTIMA 55 Phase IIb clinical trials 55 confirmatory clinical 55 viral kinetics 55 ritonavir boosted 55 riociguat 55 fosbretabulin 55 OHR/AVR# 55 sevelamer 55 nab paclitaxel 55 IFN Beta 55 dalbavancin 55 trastuzumab DM1 55 TLK# 55 evaluating tivozanib 55 telbivudine 55 Valdoxan 55 Cloretazine 55 AQ4N 55 KRN# 55 radezolid 55 Archexin 55 ChronVac C R 55 adecatumumab 55 INVEGA SUSTENNA 55 OvaRex R 55 UVIDEM 55 TELCYTA 55 latanoprost 55 MAP# 55 intravenous dosing 55 solithromycin 55 zoledronate 55 phase IIb 55 Ophena TM 55 LCP Tacro 55 Xanafide 55 low dose cytarabine 55 Specifid 55 Tyrima 55 ORMD 55 Cimzia TM 55 peg interferon 55 PREOS 55 casopitant 55 Gefitinib 55 ATACAND 55 biologic DMARD 55 plasma kallikrein inhibitor 55 Inhalation Solution 55 Itopride 55 PROCHYMAL 55 RE SURGE 55 JANUVIA 55 Factor VIIa 55 Triapine R 55 rhTSH 55 Plenaxis TM 55 orally bioavailable 55 bicifadine 55 dexpramipexole 55 baminercept 55 ganetespib 55 fostamatinib 55 sulodexide 54 FTY# fingolimod 54 telcagepant 54 menadione 54 aflibercept 54 posaconazole 54 CRLX# 54 EXPAREL ™ 54 oral FTY# 54 cethromycin 54 immunomodulatory therapy 54 safinamide 54 AMEVIVE 54 GOUT 54 agomelatine 54 DDP# 54 NP2 Enkephalin 54 viral kinetic 54 neratinib 54 Amplimexon 54 cediranib 54 PRTX 54 active comparator 54 budesonide 54 inhaled iloprost 54 huC# DM4 54 HCl capsules 54 eprotirome 54 Phase IIIb clinical 54 cystinosis patients 54 CALGB 54 alendronate 54 phase IIa 54 inecalcitol 54 strontium ranelate 54 interferon gamma 1b 54 pharmacodynamic effects 54 Oral NKTR 54 pharmacokinetic characteristics 54 Certolizumab 54 zalutumumab 54 sorafenib Nexavar 54 tiotropium 54 PRISTIQ 54 ACUROX ® 54 Tracleer R 54 S/GSK# 54 Pazopanib 54 Prosaptide 54 pharmacodynamics PD 54 HCV protease inhibitors 54 APTIVUS R 54 antiviral efficacy 54 BoNTA 54 mapatumumab 54 Clonicel 54 IMA# 54 injectable formulations 54 polymerase inhibitor 54 ARCOXIA 54 Sumatriptan OS 54 CLORETAZINE TM VNP#M 54 ELACYT 54 LCP AtorFen 54 #D#C# 54 Factor Xa inhibitor 54 NGX# 54 BeneFIX 54 lacosamide 54 enoximone 54 CCR5 antagonist 54 lumiliximab 54 paricalcitol 54 DexaSite 54 CIMZIA TM certolizumab pegol 54 selective modulator 54 serotonin norepinephrine reuptake inhibitor 54 Actimmune R 54 HQK 54 Aplidin 54 oral diclofenac 54 antiandrogen 54 double blinded randomized 54 clevidipine 54 dose regimens 54 Phase #b/#a 54 Elocalcitol 54 pharmacodynamic properties 54 dosing frequency 54 liprotamase 54 Phase IIb 54 OncoVEX GM CSF 54 SPIRIVA HandiHaler 54 Phase #b/#a trial 54 paclitaxel poliglumex 54 Tamsulosin 54 Pharmacokinetic 54 antithrombotic 54 antithrombotics 54 plasma pharmacokinetics 54 rizatriptan 54 proton pump inhibitor PPI 54 Ereska 54 taribavirin 54 AERx iDMS 54 sustained virologic response 54 afatinib 54 Diovan HCT 54 CTAP# Capsules 54 intermittent dosing 53 galiximab 53 multicenter randomized placebo controlled 53 dose cohorts 53 Fibrillex TM 53 GLYX 53 noninferiority 53 iniparib 53 Carvedilol 53 efficacy 53 Onrigin 53 doxorubicin docetaxel 53 TH# [003] 53 diabetic neuropathic pain 53 GLP toxicology studies 53 Phase IIb clinical 53 HspE7 53 aclidinium 53 tremelimumab 53 mcg BID 53 Phase 1b 53 zoledronic acid Zometa 53 M6G 53 Altastaph 53 OXi# 53 XL# SAR# 53 Phase #/#a 53 PKC# 53 dose proportionality 53 Tekamlo 53 tolevamer 53 milatuzumab 53 OMP #M# 53 biologic therapy 53 Phase IIa trial 53 standard chemotherapy regimen 53 abacavir lamivudine 53 dosage regimen 53 cobicistat 53 uric acid lowering 53 Vilazodone 53 glatiramer 53 NeuroSTAT ® 53 SomatoKine 53 SCH # 53 dacetuzumab 53 BioVant 53 ToGA 53 picoplatin 53 RE LY ® 53 Fortovase 53 Dual Opioid 53 Aliskiren 53 Imprime PGG 53 NATRECOR ® 53 caspofungin 53 topical diclofenac 53 trodusquemine 53 pimecrolimus 53 CA4P 53 placebo controlled studies 53 intravesical instillation 53 KADIAN R 53 pharmacokinetics PK 53 LEVADEX 53 SSRI SNRI 53 SinuNase TM 53 CERVARIX 53 pharmacodynamic PD 53 axitinib 53 tigecycline 53 multicentre randomized 53 PXD# 53 Zelrix 53 MICARDIS ® 53 CTA# 53 PEG INTRON 53 bevacizumab Avastin ® 53 QD dosing 53 bioequivalency 53 Vidaza azacitidine 53 IRESSA 53 Bupropion 53 PSN# [002] 53 LEP ETU 53 rimonabant #mg 53 elagolix 53 Fodosine 53 Tasimelteon 53 pegylated interferon alfa 2b 53 selective COX 2 53 platelet inhibitor 53 depsipeptide 53 tanespimycin 53 Canvaxin 53 UPLYSO 53 Phase IIa clinical 53 sorafenib tablets 53 DASISION 53 NOXAFIL Oral Suspension 53 preclinical efficacy 53 TNF alpha inhibitor 53 systemic bioavailability 53 apremilast 53 Virulizin ® 53 pramlintide metreleptin combination 53 photoprotective drug 53 efficacy tolerability 53 Eli Lilly Cymbalta 53 iSONEP 53 AERx 53 DU #b 53 mg doses 53 aripiprazole Abilify 53 JANUMET 53 peginterferon alfa 2b 53 rNAPc2 53 Ketotransdel 53 celgosivir 53 Golimumab 52 RE LY 52 clinical pharmacology studies 52 mg d 52 dose escalation 52 MGN# 52 Afatinib 52 PREZISTA r 52 ZYBRESTAT 52 ataluren 52 Bifeprunox 52 Phase 2b trial 52 peripherally acting 52 Rivaroxaban 52 pharmacodynamic parameters 52 RLAI 52 pantoprazole 52 novel histone deacetylase 52 Cloretazine R VNP#M 52 incyclinide 52 retapamulin 52 tecarfarin 52 pain palliation 52 OPAXIO 52 INCB# [002] 52 HIF PH inhibitors 52 TELINTRA 52 preclinical pharmacokinetic 52 elvitegravir 52 phase 2a 52 mg QD 52 dabigatran etexilate 52 ROCKET AF 52 EVIZON 52 vernakalant hydrochloride 52 PF # [001] 52 ProSavin 52 EMSAM 52 Phase 2a clinical 52 Excellarate 52 Synavive 52 miconazole 52 TDF FTC 52 RSD# oral 52 PPAR gamma agonists 52 vascular disrupting agents 52 Zybrestat 52 bupropion SR 52 RISPERDAL ® 52 carboplatin paclitaxel 52 fondaparinux 52 antiarrhythmic 52 Non inferiority 52 rt PA 52 VIAject R 52 ganaxolone 52 elacytarabine 52 IMGN# 52 pharmacokinetic PK 52 μmol L 52 obatoclax 52 clomipramine 52 Cleviprex TM clevidipine 52 donepezil 52 Cancidas 52 personalized immunotherapy 52 CRMD# 52 micafungin 52 tramiprosate ALZHEMED TM 52 Protelos 52 CG# [003] 52 transdermal fentanyl 52 HZT 52 AzaSite Plus 52 Noxafil 52 alfa 2a 52 paclitaxel Taxol 52 LOVENOX R 52 hydrochloride capsules 52 Crinone 52 APPRAISE 52 darunavir r 52 talactoferrin 52 PEGylated interferon beta 1a 52 lubiprostone 52 multicenter Phase II 52 bosentan 52 ACAPODENE TM 52 Carfilzomib 52 Apoptone 52 CINTREDEKIN BESUDOTOX 52 Histalean TM 52 antifibrinolytic 52 convenient dosing regimens 52 valdecoxib 52 Enjuvia 52 oral probiotic 52 ORAL HYCAMTIN 52 pharmacodynamic profiles 52 Phase 1b clinical 52 MORAb 52 AChE inhibitors 52 randomized multicenter trial 52 dose escalation clinical 52 Doxil ® 52 bevacizumab Avastin 52 Certolizumab pegol 52 coadministration 51 Spiegelmer ® 51 orally disintegrating 51 SNRI 51 rifalazil 51 immune modulating 51 mRCC 51 platelet inhibition 51 p# inhibitor 51 TNF inhibitor 51 budesonide foam 51 tolerated dose MTD 51 danazol 51 PEARL SC 51 systemic RNAi therapeutic 51 REVIVE Diabetes 51 oral Xeloda 51 etanercept Enbrel 51 lopinavir r 51 IMC A# 51 potency selectivity 51 antitumor effect 51 HMG CoA reductase inhibitors 51 eculizumab therapy 51 erythropoietic 51 telithromycin 51 randomized multicenter 51 arzoxifene 51 MEK inhibitors 51 ustekinumab 51 afamelanotide 51 antitumor efficacy 51 Cmax 51 romidepsin 51 ixabepilone 51 Phase IIIb 51 GORE VIABAHN Endoprosthesis 51 Kinoid 51 FOLFOX 51 Naprelan 51 Phase Ib clinical trials 51 temsirolimus 51 lurasidone 51 antiangiogenic therapy 51 Phase 2b clinical 51 coxib 51 Allovectin 7 ® 51 Bioavailability 51 pegylated interferon alfa 51 levocetirizine 51 Empatic 51 fulvestrant 51 KADIAN ® 51 Preclinical studies suggest 51 MULTAQ 51 Phase IIIb study 51 CYT# 51 pharmacodynamic 51 deferiprone 51 Nascobal 51 PrevOnco ™ 51 docetaxel 51 Valortim ® 51 reboxetine 51 rhEPO 51 PDE4 inhibitors 51 Kivexa 51 Advagraf 51 dose escalation trial 51 zotarolimus eluting stent 51 sulphonylureas 51 Zenvia Phase III 51 secondary efficacy endpoints 51 RoACTEMRA 51 randomized multicenter Phase III 51 BANZEL 51 ANAVEX #-# [001] 51 multitargeted 51 Combo Stent 51 antithrombotic agent 51 mg simvastatin 51 edoxaban 51 mcg ml 51 Hazard Ratio 51 pharmacokinetic pharmacodynamic 51 Zoraxel 51 OLEPTRO 51 colesevelam HCl 51 Anidulafungin 51 Phase 2a 51 ILLUMINATE 51 Sandostatin LAR 51 MBP# [001] 51 MoxDuo ® IR 51 Pharmacokinetic studies 51 pharmacokinetic studies 51 pharmacokinetic interactions 51 dosing regimens 51 Calcitonin 51 parecoxib 50 surrogate endpoint 50 Xinlay 50 randomized Phase 2b 50 cardioprotective effects 50 FM VP4 50 monotherapy 50 receptor inhibitor 50 Avastin bevacizumab 50 histone deacetylase inhibitor 50 Efficacy 50 TAXUS Stent 50 OMNARIS HFA 50 Serdaxin 50 randomized controlled clinical trials 50 beta blocker therapy 50 anticancer activity 50 eluting stent 50 Octreolin 50 antidepressant efficacy 50 BNC# 50 norethindrone acetate 50 virologic response 50 achieved statistical significance 50 lasofoxifene 50 virological suppression 50 Wellbutrin XL ® 50 SILENOR 50 plus medroxyprogesterone acetate 50 RAPAFLO R 50 placebo controlled 50 docetaxel Taxotere 50 plus prednisone 50 Duromist ™ 50 phase IIb III 50 intracellular uptake 50 antihyperglycemic 50 tegaserod 50 Mirapexin 50 celecoxib 50 thienopyridine 50 nonclinical studies 50 prospectively defined 50 docetaxel Taxotere ® 50 Lovastatin 50 Platinol 50 pCR 50 megestrol acetate 50 mg dosed twice 50 quetiapine 50 trabectedin 50 antiplatelet 50 ADAGIO study 50 AAG geldanamycin analog 50 lenalidomide dexamethasone 50 Perforomist TM Inhalation Solution 50 antifibrotic 50 Vaxfectin R 50 vinorelbine 50 paroxetine sertraline 50 leukotriene receptor antagonists 50 wilate ® 50 chemotherapeutic drug 50 TOVIAZ 50 lintuzumab 50 placebo controlled trials 50 selegiline 50 Xenazine ® 50 Adlea 50 ocular formulation 50 DSMB recommended 50 factor Xa inhibitor 50 therapeutic regimens 50 Mycamine 50 Phase IIa 50 nebulized formoterol fumarate 50 investigational protease inhibitor 50 pharmacodynamic markers 50 Vorapaxar 50 Mesafem 50 Numax 50 optimal dosing 50 HyQ 50 INVEGA ® 50 IMPACT DCM clinical 50 glucuronide 50 interferon alfa 2b 50 lucinactant 50 nonrandomized 50 Fluticasone Propionate 50 RE LY trial 50 multicenter Phase III 50 plus ribavirin 50 acitretin 50 Femara letrozole 50 fluconazole 50 varespladib 50 investigational compound 50 L PPDS 50 Pharmacokinetic PK 50 pharmacodynamic profile 50 EmbraceAC 50 pharmacokinetic parameters 50 neurologic progression 50 amrubicin 50 celecoxib Celebrex 50 Alpharadin 50 bronchodilation 50 clinically meaningful efficacy 50 Losartan 50 betamethasone dipropionate 50 XIBROM 50 erlotinib Tarceva ® 50 mg kg BID 50 Genvec 50 Zenvia 50 antipsychotic efficacy 50 Zenvia ™ 50 ZYBRESTAT fosbretabulin 50 anti leukemic 50 Trizytek 50 GRN#L 50 pharmacokinetic profile 50 SPRIX ® 50 Perforomist ™ Inhalation Solution 50 ESTRASORB 50 risedronate sodium tablets 50 noninferior 50 dosing 50 omega interferon 50 ACIPHEX 49 Pharmacokinetics PK 49 AVERROES 49 ACEON R 49 Rhinocort 49 Diamyd r vaccine 49 intravenous cyclophosphamide 49 LUMIGAN R 49 Stimuvax R 49 nonsedating antihistamine 49 favorable tolerability 49 BrachySil 49 Aptivus 49 Desmopressin 49 anecortave acetate 49 TOLAMBA 49 gemifloxacin 49 renoprotective 49 Alequel ™ 49 non inferiority 49 pharmacokinetics pharmacodynamics 49 MIST II 49 Celebrex celecoxib 49 Vectibix panitumumab 49 amifostine 49 rALLy trial 49 aspirin clopidogrel 49 postmenopausal estrogen 49 tolerability profiles 49 safety tolerability pharmacokinetics 49 cardiac toxicity 49 Intravail R 49 oral bioavailability 49 systemically administered 49 Infergen R 49 dual antiplatelet 49 Suprax R 49 low dose ritonavir 49 placebo controlled clinical trials 49 TAXUS VI 49 oxymorphone ER 49 Tolerability 49 refractory prostate cancer 49 TLR agonists 49 mGluR5 inhibition 49 multidose 49 serum uric acid sUA 49 LEVAQUIN ® 49 palifosfamide 49 mesilate 49 Boniva ibandronate 49 randomized Phase III 49 LNG IUS 49 tolerability pharmacokinetics 49 chemoradiotherapy 49 TAXUS V 49 Phase Ia 49 CYPHER R Sirolimus eluting 49 MyVax 49 antitumor effects 49 tolerability profile 49 PPAR gamma agonist 49 calcium antagonist 49 rivaroxaban 49 prulifloxacin 49 roflumilast 49 conventional DMARDs 49 oral deforolimus 49 clopidogrel Plavix 49 pharmacodynamics 49 Starlix 49 convenient dosing regimen 49 Darinaparsin 49 Lupron Depot 49 antidiabetic medications 49 Phase Ib 49 TMC# C# 49 phase IIb study 49 urate lowering 49 MAO inhibitor 49 ranolazine 49 antiepileptics 49 VIR# 49 ruxolitinib 49 HAQ DI 49 pharmacokinetic equivalence 49 R roscovitine 49 Hyalgan 48 Phase III trials 48 Istalol 48 AERx ® 48 alemtuzumab MS 48 TRIZIVIR 48 REOPRO 48 pharmacokinetic properties 48 Multimeric 48 Tranexamic acid 48 vivo potency 48 intravenously administered 48 TRANSFORMS 48 antiresorptive 48 metastatic RCC 48 bevacizumab Avastin Genentech 48 AUC0 48 NEVO TM 48 cefdinir